John LeGall, MD, MBA

John LeGall is Vice President Clinical Development at Allogene Therapeutics. At Allogene, Dr. LeGall is serving as the principal investigator of ALLO-316, an allogeneic CAR-T cell therapy. Prior to Allogene, Dr. LeGall has held multiple leadership roles across the Cell and Gene Therapy space. He has served in clinical development roles at Instil Bio focused on development of TIL therapies and at Kite Pharma focused on CAR-T cell therapies. Dr. LeGall received his MD from Columbia University and MBA from Columbia Business School, and completed a clinical fellowship in Oncology and Hematology at Johns Hopkins Hospital and Immunotherapy at the National Cancer Institute.